ERβ repurposes EZH2 to suppress oncogenic NFκB signaling in TNBC

Project: Research project

Project Details

Description

PROJECT NARRATIVE Triple negative breast cancer (TNBC) is an aggressive form of the disease with few treatment options, high recurrence rates and disproportionately higher mortality rates. This proposal involves elucidating the mechanisms by which estrogen receptor beta (ERβ) elicits potent anti-cancer effects in TNBC and determining the utility of specifically targeting this receptor, alone and in combination with established chemotherapy regimens, for therapeutic purposes. Results of the proposed study are expected to contribute to the development of a new class of therapies, and allow for better stratification of patients to specific forms of chemotherapy, ultimately resulting in improved outcomes for thousands of patients each year.
StatusActive
Effective start/end date1/1/2112/31/22

Funding

  • National Cancer Institute: $458,861.00
  • National Cancer Institute: $476,895.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.